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Abstract
Background: All rigorous primary cardiovascular disease (CVD) prevention guidelines recommend absolute CVD risk
scores to identify high- and low-risk patients, but laboratory testing can be impractical in low- and middle-income
countries. The purpose of this study was to compare the ranking performance of a simple, non-laboratory-based
risk score to laboratory-based scores in various South African populations.
Methods: We calculated and compared 10-year CVD (or coronary heart disease (CHD)) risk for 14,772 adults from
thirteen cross-sectional South African populations (data collected from 1987 to 2009). Risk characterization performance
for the non-laboratory-based score was assessed by comparing rankings of risk with six laboratory-based scores
(three versions of Framingham risk, SCORE for high- and low-risk countries, and CUORE) using Spearman rank correlation
and percent of population equivalently characterized as ‘high’ or ‘low’ risk. Total 10-year non-laboratory-based risk of CVD
death was also calculated for a representative cross-section from the 1998 South African Demographic Health Survey
(DHS, n = 9,379) to estimate the national burden of CVD mortality risk.
Results: Spearman correlation coefficients for the non-laboratory-based score with the laboratory-based scores
ranged from 0.88 to 0.986. Using conventional thresholds for CVD risk (10% to 20% 10-year CVD risk), 90% to 92%
of men and 94% to 97% of women were equivalently characterized as ‘high’ or ‘low’ risk using the non-laboratory-based
and Framingham (2008) CVD risk score. These results were robust across the six risk scores evaluated and the thirteen
cross-sectional datasets, with few exceptions (lower agreement between the non-laboratory-based and Framingham
(1991) CHD risk scores). Approximately 18% of adults in the DHS population were characterized as ‘high CVD risk’
(10-year CVD death risk >20%) using the non-laboratory-based score.
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Conclusions: We found a high level of correlation between a simple, non-laboratory-based CVD risk score and
commonly-used laboratory-based risk scores. The burden of CVD mortality risk was high for men and women in
South Africa. The policy and clinical implications are that fast, low-cost screening tools can lead to similar risk
assessment results compared to time- and resource-intensive approaches. Until setting-specific cohort studies can
derive and validate country-specific risk scores, non-laboratory-based CVD risk assessment could be an effective
and efficient primary CVD screening approach in South Africa.
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Background
The multiple risk factors for cardiovascular diseases (CVD)
frequently occur simultaneously in individuals at risk. Be-
cause of this clustering, risk factors interact synergistically
to increase the level of CVD risk to such an extent that the
resulting absolute risk levels achieved are much higher than
would be anticipated when considering the individual risk
factors. These patients with the highest level of absolute
CVD risk will benefit substantially if they are identified and
all their risk factors diagnosed early and treated appropri-
ately [1]. In fact, such an absolute CVD risk approach has
been shown to be more cost-effective than treating patients’
individual risk factors to prevent CVD [2]. The calculation
of the absolute CVD risk is usually based on age, gender,
tobacco use status, blood pressure levels and blood choles-
terol levels as was done with data from the Framingham
study [3]. A number of similar formulations of absolute
CVD risk have been proposed in a variety of settings where
cohort studies were conducted to evaluate the usefulness of
absolute CVD risk scores in predicting CVD events [4-7].
The absolute risk determination approach holds particu-
lar promise for resource scarce settings where the limited
resources could best be utilized by identifying those at
highest absolute CVD risk. However, blood lipid determi-
nations for screening purposes will be far too costly in
most developing country settings with limited resources
and consequently are unlikely to be adopted as policy in
these settings. This has prompted an investigation into the
possibility of using other known CVD risk factors that are
easier and less costly to measure in the place of CVD risk
factors that require costly laboratory tests when calculat-
ing absolute CVD risk scores. This work compared the
ability to predict first time fatal and non-fatal CVD events
in the National Health and Nutrition Examination Survey
(NHANES) I follow-up study cohort by two risk predic-
tion models: the laboratory-based Framingham risk score
and a non-laboratory-based model, which required only
history and physical examination measures [8]. The non-
laboratory-based model used the same risk factors but
replaced total cholesterol with body-mass index and pre-
dicted CVD events equally accurately. This suggested that
the less costly non-laboratory absolute CVD risk score
can effectively be used in resource scare settings.
The exchangeability of the non-laboratory-based score
with commonly-used laboratory-based approaches has
been validated in a United States population [9]. In an at-
tempt to evaluate the effectiveness of the non-laboratory
absolute CVD risk score in a developing country setting,
we compared the ranking of individuals using the non-
laboratory-based score with six other absolute risk scores
based on laboratory testing in thirteen data sets of
cross-sectional CVD risk factor surveys conducted in
South Africa between 1987 and 2009.
Methods
The main analyses in this study were based on the
comparison of (10-year) individual-level absolute CVD
(or coronary heart disease (CHD)) risk predictions using
the non-laboratory-based [8] (Table 1) and six laboratory-
based risk scores [5,10-12]. The study populations that had
been used to develop each absolute risk score, the inputs
required for each score, and the composite outcome that
each score was designed to predict are described in Table 1.
Beta-coefficients and specific details for each score are
described in further detail in Additional file 1. Among
the laboratory-based risk scores, the Framingham CVD
risk equations are the most well-known (globally) and
commonly-used in South Africa [13]. We, therefore,
focused on the risk characterization comparisons between
the recently developed Framingham (2008) CVD score [11]
and the non-laboratory score in our study, although
comparisons with the non-laboratory score were performed
for all six of the laboratory-based scores.
The South African study populations used for the
comparison comprised thirteen data sets of cross-sectional
CVD risk factor surveys in random samples of participants
25 to 74 years old from specific language/geography-based
populations [14-20]. Data from the PURE, CRIBSA, and
Phoenix studies have not been published but were provided
to us from the principal investigator of each study. The data
were collected using similar standardized methods and
funds for the laboratory analysis were included in the re-
search grants of each study. These studies were selected, in
part, so we could assess potential differences across urban/
rural status, population group, and time. Table 2 outlines
the study populations, years of data collection, and basic
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demographics (age range and percent female) for each
dataset. Because the average clinical characteristics of
the Phoenix dataset have not yet been disseminated,
this information is not reported in this study. The
population of interest for this analysis was comprised
of the aggregate collection of 14,772 individuals from
all of the thirteen South African datasets.
Correlation in risk characterization was based on
comparisons of individual-level, score-specific rank-
ings of absolute CVD risk for the non-laboratory-based
score relative to the six laboratory-based scores. The first
step in our analysis was to calculate individual-level risk
predictions for each of the seven scores included in the
study. Individuals were subsequently assigned ranks for
each risk score by sex. These ranks were used to assess cor-
relation in dichotomous risk characterization for the non-
laboratory-based score compared to each laboratory-based
risk score. Using a threshold of >20% 10-year Framingham
(2008) CVD risk, individuals were characterized as ‘high’ or
‘low’ risk for each score based on their score-specific rank.
We then found the risk level that was equivalent to the
same proportion of events using each score. For example, if
Table 1 Study populations, inputs, and outcomes used to construct each of the risk scores used in this study
Score Populationa Inputs Outcome
Non-laboratory-based
(Gaziano et al., 2008) [8]
NHANES I (US, 1971 to 1975) Age, sex, smoking, diabetes, systolic blood
pressure, treatment for hypertension, BMI
CVD death, MI, stroke, CHF,
coronary bypass, PTCA
Framingham CVD 2008
(D’Agostino et al., 2008) [11]
Framingham, MA, US (1968 to 1987) Age, sex, smoking, diabetes, systolic blood
pressure, treatment for hypertension, total
cholesterol, HDL cholesterol
MI, angina, coronary insufficiency,
CHD death, stroke, TIA, CHF, PVD,
CVD death
Framingham CVD
(Anderson et al., 1991) [10]
Framingham, MA, (US., 1968 to 1975) Age, sex, smoking, diabetes, systolic blood
pressure, total cholesterol, HDL cholesterol
Same as above
Framingham CHD
(Anderson et al., 1991) [10]
Same as above Same as above MI, CHD death, angina, coronary
insufficiency
SCORE, high risk
(Conroy et al., 2003) [4]
High risk European countriesb Age, sex, smoking, systolic blood pressure,
total cholesterol
Death from: hypertensive disease,
IHD, cerebrovascular disease
SCORE, low risk
(Conroy et al., 2003) [4]
Low risk European countriesc Same as above Same as above
CUORE (Giampaoli et al., 2007) [12] Italy (1983 to 1997) Age, sex, smoking, diabetes, systolic blood
pressure, treatment for hypertension, total
cholesterol, HDL cholesterol
Fatal and non-fatal MI or stroke
aYears indicate when baseline values were collected; bapplicable for all non-low risk European countries; capplicable for Belgium, France, Greece, Italy,
Luxembourg, Portugal, Spain, and Switzerland. BMI, body-mass index; CHD coronary heart disease, CHF congestive heart failure, CVD cardiovascular disease,
HDL high-density lipoprotein, IHD ischemic heart disease, MI myocardial infarction, NHANES National Health and Nutrition Examination Survey, PTCA percutaneous
transluminal coronary angioplasty, PVD peripheral vascular disease, TIA transient ischemic attack.
Table 2 Description of the 13 cross-sectional cardiovascular disease (CVD) risk factor studies
Dataset Numbera Population description Year(s) of data collection % Female Age range (years)
DHS [22] 9,379 Representative South African 1998 60.2% 25 to 74
Aggregate 14,772 Aggregate of 13 datasets below 1987 to 2009 61.0% 25 to 74
BRISK [17] 644 African, urban Xhosa speaking 1990 55.4% 25 to 64
CRIBSA 1,003 African, urban, Xhosa speaking, 2008 64.3% 25 to 74
Mangaung [14] 718 African, urban, Sesotho speaking 1990 61.5% 25 to 74
QwaQwa [14] 782 African, rural, Sesotho speaking 1990 68.6% 25 to 74
AHA-FS urban [20] 385 African, urban Sesotho speaking 2009 76.8% 26 to 64
AHA-FS rural [20] 512 African, rural, Sesotho speaking 2007 70.1% 26 to 65
PURE, Urban 903 African, urban, Tswana-speaking 2005 58.9% 29 to 74
PURE, Rural 933 African, rural, Tswana-speaking 2005 65.2% 32 to 74
KwaZulu-Natal [15] 742 African, rural, Zulu-speaking 1999 82.5% 25 to 74
CRISIC [18] 775 Colored, urban, community 1990 50.7% 25 to 64
Mamre [19] 695 Colored, rural, community 1996 57.3% 25 to 74
KORIS [16] 5,608 White, rural, community 1987 54.1% 25 to 68
Phoenix 1,072 Indian, urban, community 2007-2008 73.6% 25 to 68
arandom sample.
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the CVD risk score using the Framingham risk score identi-
fied 15% of the population above 20% 10-year risk then we
used the equivalent risk score of the non-laboratory risk
score to identify 15% of the population. The CUORE risk
score identified similar proportions of the population
as did the Framingham CVD risk and the SCORE risk
score threshold of >5% fatal events is equivalent to the
Framingham CVD score. An alternative threshold of
10-year Framingham CHD risk >20% was also assessed.
Percent agreement between the non-laboratory-based
score and each of the laboratory-based scores was cal-
culated by adding the proportions of individuals who
were equivalently characterized as ‘high’ or ‘low’ risk
by both scores. Spearman rank correlation coefficients
were computed for the non-laboratory-based score com-
pared to each of the laboratory-based scores to assess
the correlations in the rankings across the full spectrum
of risk thresholds. Pearson correlation coefficients were
not reported because CVD risk prediction values were
not normally distributed [21].
We also analyzed data from the 1998 South African
Health and Demographic Survey (DHS), which has
all the necessary information needed to complete the
non-laboratory-based risk score [22]. This nationally
representative sample allows us to partially assess whether
our results from the cohorts might be generalizable for
national primary CVD screening practice. The analyses in-
volving comparison to the laboratory-based scores, how-
ever, could not be performed on the DHS data because it
does not contain the blood cholesterol values needed to
compute the laboratory-based risk assessments.
As a separate analysis of interest, we computed
individual-level 10-year risk of CVD death based on the
non-laboratory-based risk factors to assess the distribu-
tion of absolute CVD risk in the study cohorts and DHS
populations. In this second analysis where we look at
the 10-year risk of the DHS group we apply the CVD
death only score because given the lack of a registry or
widely available electronic hospital records for non-fatal
MI or stroke in South Africa the only outcome that we will
be able to validate in the near future is CVD death and,
thus, use this score for projections. We also chose CVD
death risk for these analyses to focus on the most severe
events (that is, CVD death), as opposed to softer outcomes
(such as angina events or revascularization procedures) that
are harder to confirm currently in South Africa with limited
registry data. These analyses served two functions: 1) to
compare the distribution of risk in the representative DHS
population to the study population; and 2) to characterize
the predicted 10-year CVD mortality risk burden among
South African adults.
Each of the studies in South Africa underwent inde-
pendent study reviews under the local institutional review
board (IRB)/ethics committees including the University
of the Orange Free State Ethics Committee for Clinical
Trials, the University of Free State Ethics Committee of
the Faculty of Health Sciences, the Ethics Committee of the
North-West University, the Ethics Committee at the
University of Cape Town, the University of KwaZulu-
Natal Biomedical Research Ethics Committee, and the
Ethics Committee of the Medical Research Council of
South Africa. Informed consent was obtained from all
study participants under local IRB supervision. Only
non-identifiable data sets were used and the Ethics
Committee of the University of Cape Town approved
of the study to evaluate CVD risk.
Results
Table 3 shows the population characteristics of thirteen
South African populations included in the main study
population, the aggregate population that comprised
these thirteen datasets, and the representative 1998 South
Africa DHS population. The aggregate study population
had similar characteristics to the DHS population with re-
spect to sex, age and BMI but there were observed differ-
ences regarding current smokers (43.7% in DHS compared
to 33.0% in the aggregate study population), diabetes
(3.9% and 6.0%, respectively), blood pressure treatment
(8.8% and 15.0%, respectively) and systolic blood pressure
(123.9 and 133.9 mmHg, respectively). In addition to
reporting the average levels of each risk factor used to
calculated each of the individual-level risk predictions,
the table includes the proportions of the population
with >20% 10-year CVD death risk based on the non-
laboratory-based risk factors (age-adjusted for the WHO
Segi reference population). The proportion of the study
population at high risk (19.9%) using this threshold
was similar to the DHS population (17.9%). Although
the proportion of the population at ‘high-risk’ ranged
from 10.4% to 26.6% across the individual study datasets,
there were no observable trends in the percent of the popu-
lation at ‘high-risk’ by urban/rural status, language, or year
of data collection. Non-African/Non-colored populations
(Koris and Phoenix) had lower CVD risk (15.4% and 14.0%)
compared to the study average (19.9%).
Tables 4 and 5 display the Spearman rank correlation
coefficients for the non-laboratory-based risk score com-
pared to each of the six laboratory-based scores for each
of the 13 study populations and the aggregate dataset.
For men (Table 4) and women (Table 5) in the aggregate
study population, the Spearman correlation was >0.93 for
the laboratory-based scores compared to scores that were
intended to predicted CVD events (that is, all scores aside
from the Framingham CHD function). For comparison
purposes, a 20% Framingham CVD risk and the 20%
CUORE score of fatal and non-fatal events is equivalent to
the SCORE risk of 5% for fatal events only. In general,
the correlation coefficients were highest for the non-
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laboratory-based score compared to the SCORE and
CUORE functions, followed by the Framingham CVD
scores, then the Framingham CHD score. The ranges
of correlation coefficients across the 13 study popula-
tions for the non-laboratory-based score compared to
the Framingham (2008) CVD score were 0.877 to 0.964
(in men) and 0.888 to 0.950 (in women). Similar results
were seen for the other risk scores with few exceptions.
Figures 1a (for men) and 1b (for women) plot individuals
in the aggregate study population based on rankings of
risk (in ascending order) for the non-laboratory-based
(vertical axis) and Framingham (2008) CVD (horizontal axis)
risk scores. Based on a risk threshold that corresponds
to 10-year Framingham (2008) CVD risk >20%, there
was 89.8% and 93.9% agreement in risk characterization
between the non-laboratory-based and the Framingham
Table 4 Spearman rank correlation results for six laboratory-based risk scores, each compared to non-laboratory-based
risk score, men
Dataset Number Fr_CVD_08 [11] Fr_CVD_91 [10] Fr_CHD_91 [10] SCORE_h [4]a SCORE_l [4]a CUORE [12]
Aggregate 5,751 0.939 0.950 0.883 0.985 0.986 0.957
BRISK 287 0.964 0.969 0.931 0.988 0.989 0.970
CRIBSA 357 0.963 0.967 0.922 0.987 0.988 0.974
Mangaung 276 0.952 0.961 0.900 0.985 0.986 0.967
QwaQwa 247 0.951 0.960 0.896 0.988 0.989 0.967
AHA-FS Urban 90 0.895 0.896 0.835 0.960 0.962 0.969
AHA-FS Rural 151 0.906 0.903 0.797 0.967 0.968 0.959
PURE, Urban 364 0.877 0.893 0.751 0.974 0.978 0.925
PURE, Rural 326 0.910 0.919 0.818 0.977 0.980 0.938
KwaZulu-Natal 130 0.944 0.943 0.881 0.981 0.981 0.968
CRISIC 382 0.945 0.956 0.891 0.987 0.988 0.952
Mamre 296 0.957 0.966 0.919 0.986 0.987 0.952
KORIS 2,571 0.951 0.959 0.914 0.988 0.989 0.966
Phoenix 274 0.959 0.962 0.921 0.963 0.966 0.971
aFramingham 10-year CVD risk of >20% of fatal and non-fatal events is equivalent to 5% risk of fatal events for SCORE. CHD coronary heart disease,
CVD cardiovascular disease, Fr Framingham.
Table 3 The characteristics and CVD risk factor profiles of the study population 25 to 74 years old



















DHS[22] 9,379 60.2% 44.5 43.7% 3.85%b 8.8% 123.9 n/a n/a 26.6 17.9%
Aggregate 14,772 61.0% 46.5 33.0% 6.0% 15.0% 133.9 50.8 206.5 26.9 19.9%
BRISK 644 55.4% 39.9 33.0% 4.0%b 9.0% 120.2 54.2 166.7 27.3 10.4%
CRIBSA 1,003 64.3% 43.7 27.0% 10.0%c 20.0% 126.3 45.3 170.7 30.1 20.6%
Mangaung 718 61.5% 46.6 35.0% 7.0%c 13.0% 141.9 52.6 195.1 27.3 23.1%
QwaQwa 782 68.6% 48.1 26.0% 6.0%c 12.0% 141.0 46.7 184.3 27.3 19.9%
AHA-FS urban 385 76.8% 44.5 22.0% 8.0%b 25.0% 135.8 46.6 162.3 27.7 12.1%
AHA-FS rural 512 70.1% 47.0 41.0% 10.0%b 51.0% 143.5 45.6 190.2 26.8 17.5%
PURE, Urban 903 58.9% 49.7 54.0% 2.0%b 10.0% 136.4 58.9 195.3 24.9 24.4%
PURE, Rural 933 65.2% 47.9 51.0% 1.0%b 6.0% 129.3 58.6 191.8 24.0 20.2%
KwaZulu-Natal 742 82.5% 49.0 15.0% 1.0%b 15.0% 128.1 48.0 160.7 26.1 14.9%
CRISIC 775 50.7% 44.0 55.0% 6.0%b 6.0% 134.1 57.5 230.8 26.2 13.6%
Mamre 695 57.3% 43.4 52.0% 6,0%c 47.0% 136.5 50.8 212.9 27.0 26.6%
KORIS 5,608 54.1% 47.0 27.0% 3.0%b 7.0% 135.1 49.6 230.2 26.6 15.4%
Phoenix 1,072 73.6% 47.6 25.0% 22.0%c 39.0% 131.8 50.0 214.7 28.4 14.0%
aAge standardized against WHO Segi (‘world’) reference population (gender weighted for South African population); bSelf report; cGTT. See Table 2 for references.
HDL high density lipoprotein.
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(2008) CVD risk scores, for men and women, respectively.
Table 6 (for men) and Table 7 (for women) show the
complete risk characterization agreement results for the
non-laboratory-based score compared to each of the six
laboratory-based scores and for each of the 13 study
populations in addition to the aggregate study dataset.
The risk characterization agreement findings were simi-
lar to the Spearman rank correlation results both in
terms of higher agreement/correlation with CVD scores
(as opposed to the Framingham CHD score).
Figure 2 shows the distribution of 10-year non-laboratory-
based CVD death risk in the aggregate study and the
representative 1998 South Africa DHS populations by
sex (age-adjusted to WHO Segi reference population).
The largest proportion of each population belonged in
the <10% risk group, although 30% of the populations
had 10-year non-laboratory-based CVD death risk >10%.
Approximately 2% to 3% of each population was at greater
than 60% 10-year risk of dying from CVD. Figure 3 shows
the percent of the same populations that were above se-
lected 10-year CVD death risk thresholds based on non-
laboratory-based risk factors. More than 17% of individuals
in each population were at greater than 20% 10-year CVD
death risk (which is close to the general recommended risk
thresholds for treatment for medium-income countries),
and 4% to 6% of the aggregate study populations were
at greater than 40% 10-year CVD death risk [23]. The
aggregate study population had slightly more individuals at
higher risk in the lowest category considered (>20% risk),
while the proportions of the aggregate study population
above each threshold >25% were similar to the DHS popu-
lation (the differences were less than 3.3% for each
threshold, in absolute terms). There were small differences
in the gender comparisons, with the aggregate study popu-
lation having slightly higher proportions of men at high
risk compared to the DHS population (women were
similar across these populations).
Discussion
In this study, we found that a non-laboratory-based CVD
risk score, when compared to six versions of laboratory-
based Framingham, SCORE and CUORE equations,
similarly ranked individuals and characterized CVD
risk in all 13 cohorts studied. We observed strong
agreement in risk characterization between the non-
laboratory-based and laboratory-based scores in all
the cohorts. This was true for the aggregate of the co-
horts and in each of the cohorts, which had a wide
range of overall risk suggesting the non-laboratory-based
risk tool performs as well in low-risk groups as it does in
high-risk populations. The greatest agreement was with
the SCORE risk tool with more than 96% agreement in
both men and women. More than 92% of men and 97% of
women were equivalently characterized as ‘high’ or ‘low’
risk by non-laboratory-based and laboratory-based scores
using a risk threshold based on a threshold commonly
used in guidelines (10-year CHD risk >20 [24]. At a risk of
5% in both the high and low risk populations, the SCORE
equation is equivalent to the fatal and non-fatal threshold
of 20% for Framingham CVD risk.
Correlation at the CVD risk threshold of >20% was
highest for the laboratory-based CVD outcome scores,
with the older Framingham CHD only score slightly lower.
In general, the correlation was greater for women than for
Table 5 Spearman rank correlation results for six laboratory-based risk scores, each compared to non-laboratory-based
risk score, women
Dataset Number Fr_CVD_08 [11] Fr_CVD_91 [10] Fr_CHD_91 [10] SCORE_h [4]a SCORE_l [4]a CUORE [12]
Aggregate 9,021 0.933 0.937 0.925 0.984 0.985 0.969
BRISK 357 0.938 0.949 0.968 0.992 0.992 0.964
CRIBSA 646 0.944 0.948 0.950 0.987 0.987 0.977
Mangaung 442 0.945 0.943 0.935 0.989 0.989 0.974
QwaQwa 535 0.943 0.951 0.933 0.991 0.992 0.981
AHA-FS Urban 295 0.918 0.912 0.904 0.978 0.978 0.964
AHA-FS Rural 361 0.910 0.903 0.884 0.967 0.969 0.956
PURE, Urban 539 0.904 0.889 0.830 0.977 0.979 0.949
PURE, Rural 607 0.888 0.884 0.844 0.975 0.977 0.930
KwaZulu-Natal 612 0.944 0.958 0.936 0.991 0.992 0.981
CRISIC 393 0.950 0.944 0.950 0.990 0.990 0.961
Mamre 399 0.949 0.944 0.953 0.989 0.989 0.952
KORIS 3,037 0.950 0.951 0.937 0.991 0.991 0.974
Phoenix 798 0.909 0.901 0.895 0.964 0.965 0.966
aFramingham 10-year CVD risk of >20% of fatal and non-fatal events is equivalent to 5% risk of fatal events for SCORE. CHD coronary heart disease, CVD
cardiovascular disease, Fr Framingham.
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men. In men, using the 1991 Framingham CHD score, the
correlations for two cohorts, AHA-FS rural and the PURE
urban, were slightly lower (0.797, 0.751, respectively).
This is important as there has been a movement for risk
prediction tools to include both stroke and ischemic
heart disease given that many low- and middle-income
countries, including South Africa, have a higher propor-
tion of stroke in the total CVD events. Further, reductions
in most risk factors for ischemic heart disease also reduce
stroke and, thus, a risk prediction tool including both is
more in line with clinical activities. However, this level
of correlation is still considered ‘high correlation’ being
greater than 0.7 if not ‘very high correlation’ for correla-
tions greater than 0.9 [25].
The ability to assess risk without the requirement of
expensive laboratory blood tests is important in many
low-income settings for multiple reasons. The first in-
cludes its ability to correctly classify patients at the thresh-
olds that most prevention guidelines choose for initiating
treatment. Other considerations include practicality, cost
and feasibility, in particular providing clinicians with the
opportunity to make a treatment decision during a single
clinic visit. This obviates the need for a laboratory test and
a second patient visit to review the results and plan man-
agement with a resultant reduction of costs and the poten-
tial for non-attendance at the follow up visit. The cost of
cholesterol testing and the follow-up clinic visit in South
Africa is more than US $30. Testing for cholesterol for the
Figure 1 Rank variables for the non-laboratory-based risk score are plotted against rank variables for the Framingham (2008) CVD
score for adults 25 to 74 years old with complete data in the aggregate study population. Larger ranks indicate greater CVD risk. Based on
a risk threshold that corresponds to 10-year Framingham (2008) CVD risk >20%, 92.3% of men (panel a, shaded regions) and 94.0% of women
(panel b, shaded regions) would be similarly characterized as high or low risk by the non-laboratory-based and Framingham (2008) CVD risk scores.
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adult population even at a frequency of every five years
would cost $110 million annually. The annual cost of
treating a patient on generic simvastatin can be less than
$20 [26] (less than the cost of testing and follow-up visits)
which on an annual basis for all those above 20% 10-year
risk would equal nearly $60 million. Thus, money saved
from excessive laboratory testing can easily offset the cost
of treating those at high risk with an additional savings of
nearly $50 million. In addition to these savings would be
the added benefit of preventing more premature deaths
and disabling myocardial infarctions and strokes. Further-
more, patients, their families or members of the public,
with access to a blood pressure device, can calculate their
own risk and present themselves to facilities for further
evaluation. This opens up the potential for increased
opportunistic screening. Furthermore, it could lead to
Table 6 Risk categorization results for six laboratory-based risk scores, each compared to non-laboratory-based risk
score, mena
Dataset Number Fr_CVD_08 Fr_CVD_91 Fr_CHD_91 SCORE_h SCORE_l CUORE
Aggregate 5,751 89.8% 91.0% 86.4% 95.2% 95.6% 92.5%
BRISK 287 97.9% 97.2% 97.2% 99.3% 99.3% 97.9%
CRIBSA 357 93.3% 92.2% 91.6% 93.3% 93.8% 95.0%
Mangaung 276 90.5% 91.3% 85.5% 95.6% 95.6% 93.5%
QwaQwa 247 94.3% 94.3% 91.0% 97.6% 96.7% 95.9%
AHA-FS Urban 90 88.9% 91.1% 86.7% 93.3% 95.6% 95.6%
AHA-FS Rural 151 85.6% 84.9% 78.1% 94.5% 94.5% 90.4%
PURE, Urban 364 95.7% 95.7% 92.1% 97.6% 97.6% 97.0%
PURE, Rural 326 90.1% 90.7% 88.9% 95.1% 95.1% 90.7%
KwaZulu-Natal 130 87.6% 84.5% 81.4% 93.8% 92.2% 92.2%
CRISIC 382 96.9% 96.6% 94.8% 98.7% 99.0% 97.7%
Mamre 296 94.6% 93.2% 89.8% 96.6% 96.6% 95.3%
KORIS 2,571 90.9% 91.8% 88.0% 95.6% 96.0% 93.5%
Phoenix 274 92.7% 91.2% 86.1% 90.5% 90.5% 94.9%
Aggregateb 92.1% 93.0% 89.6% 95.5% 95.9% 94.2%
a‘Agreement’ based on dichotomous risk categorization corresponding to 10-year Framingham (2008) CVD risk >20%, unless otherwise noted. For SCORE this is
equivalent to a 5% fatal CVD risk; bthreshold of 10-year Framingham CHD risk >20%. CHD coronary heart disease, CVD cardiovascular disease, Fr Framingham.
Table 7 Risk categorization results for six laboratory-based risk scores, each compared to non-laboratory-based risk
score, womena
Dataset Number Fr_CVD_08 Fr_CVD_91 Fr_CHD_91 SCORE_h SCORE_l CUORE
Aggregate 9,021 93.9% 94.0% 91.7% 95.8% 95.9% 96.2%
BRISK 357 97.2% 97.8% 97.8% 97.8% 97.8% 97.8%
CRIBSA 646 95.7% 95.4% 94.4% 96.6% 96.9% 97.8%
Mangaung 442 92.7% 92.3% 89.1% 95.9% 95.9% 94.5%
QwaQwa 535 92.1% 91.0% 87.7% 95.5% 95.5% 95.1%
AHA-FS Urban 295 97.3% 97.3% 96.6% 96.6% 96.6% 97.3%
AHA-FS Rural 361 92.8% 92.0% 89.7% 92.6% 92.6% 93.7%
PURE, Urban 539 92.8% 93.2% 89.0% 96.6% 97.0% 95.8%
PURE, Rural 607 94.4% 94.1% 92.1% 97.7% 98.0% 96.4%
KwaZulu-Natal 612 96.7% 97.7% 96.4% 98.2% 98.2% 99.0%
CRISIC 393 94.7% 94.9% 93.7% 97.7% 98.0% 96.5%
Mamre 399 94.0% 93.5% 91.0% 95.5% 96.0% 95.5%
KORIS 3,037 92.8% 92.8% 89.7% 95.1% 95.3% 95.0%
PHOENIX 798 91.2% 90.9% 89.2% 91.9% 92.2% 94.2%
Aggregateb 9,021 97.1% 97.2% 96.3% 98.1% 98.3% 97.9%
a‘Agreement’ based on dichotomous risk categorization corresponding to 10-year Framingham (2008) CVD risk >20%, unless otherwise noted; bthreshold of 10-
year Framingham CHD risk >20%. CHD coronary heart disease, CVD cardiovascular disease, Fr Framingham.
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improved risk stratification for those who may be treated
so that limited medications go to those who need it most.
Using the non-laboratory-based screening tool, nearly
18% of the DHS and aggregate study populations would
have a 10-year CVD death risk greater than 20%. What
is striking is that using the 1998 Demographic Health
Survey population, the risk for women is only slightly
lower than for men, which is not the case for most
developed populations where men have a considerably
higher risk, at least in the middle-aged populations. How-
ever, in the DHS and in many of the cohorts included in
the analysis, while smoking rates tend to be higher for
men, the opposite is true for diabetes and obesity and
hypertension in the elderly. The obesity rates are almost
double and the diabetes rate is nearly 50% greater for
women than for men [27]. These differences suggest that
Figure 2 Histograms of 10-year non-laboratory-based CVD death risk are plotted for the aggregate study population and the representative
DHS (South Africa, 1998) populations by sex for adults ages 25–74 years (age-adjusted for WHO Segi ‘world’ reference population).
The study population has a slightly higher risk profile compared to the DHS population in the middle ranges (10% to 30% to 40%), although
the overall distributions of risk are mostly similar between these populations for both men and women. Histogram of non-laboratory-based
risk (10-year risk of CVD death) for adults in the study sample and DHS 98 population. CVD, cardiovascular disease; DHS, Health and
Demographic Survey; WHO, World Health Organization.
Figure 3 Percentages of adults ages 25–74 years from the aggregate study population and the representative DHS (South Africa, 1998)
populations that are greater than specified non-laboratory-based 10-year CVD death risk thresholds are plotted by sex (age-adjusted for
WHO Segi ‘world’ reference population). For men, the study population has a slightly higher risk profile compared to the DHS population in the
lower-to-middle risk thresholds (>20% to >30%), although the overall distributions of risk are mostly similar between these populations for both men
and women. Percent of adults in the study sample, and DHS 98 population, above selected non-laboratory-based thresholds (10-year CVD death risk).
CVD, cardiovascular disease; DHS, Health and Demographic Survey; WHO, World Health Organization.
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South African women, in particular, could be facing a
greater burden compared to men, especially as smoking
rates for men continue to decline.
One limitation of our analysis is that the risk discrimin-
ation and validation performance of the non-laboratory-
based risk score has not been validated in a longitudinal
South African cohort study. The lack of reliable death data
for these cross-sectional cohorts makes it impossible at
this time to validate any prediction score for CVD death.
Having a cohort study with death data would also allow us
to assess the level of correct classification and misclassifi-
cation between the different risk scores. It is also possible
that the non-laboratory-based risk score may over- or
underestimate the true risk, but that is true for all the risk
scores compared in the analysis. This is also true for most
individual risk factors on which developing countries base
their guidelines. Unfortunately, few low-income countries
have cohort data to make these estimates. No risk score
has been validated in South Africa nor, for that matter, in
most populations in low- and middle-income countries,
except China [28]. However, studies to validate the risk
score are ongoing in South Africa but this data will not be
available for nearly five years. However, the clinical need
to risk stratify patients exists now. Our results suggest that
using the non-laboratory-based scores will classify people
similarly in the meantime as those which rely on
laboratory-based information—neither of which have been
validated in developing countries. Previous analysis in the
US has shown that less than 7% disagreement occurs in
risk classification [9]. Further, the WHO/International
Society of Hypertension (ISH) risk charts have not been
validated in individual country populations but are being
promoted for screening. However, all the scores we evalu-
ated will identify the same high risk people. So, if a country
is using one of the laboratory-based risk tools, it could sub-
stitute a non-laboratory based tool for it and identity the
same group for less cost. The WHO/ISH risk charts were
not included in our analyses because the underlying risk
functions are not publicly available [23].
Conclusions
In summary, we found that a non-laboratory-based CVD
risk assessment tool ranked individuals nearly identically
compared to risk scores that require additional expensive
cholesterol tests. Using the non-laboratory-based risk as-
sessment tool, we estimate that nearly 20% of the South
African adult population is at high CVD risk. Health
care providers that have limited resources and time in
overcrowded primary health centers in South Africa
can assess risk and make treatment decisions in a much
more timely and inexpensive manner using results similar
to those obtained using blood-based risk tools. Further,
this risk factor information can be obtained non-invasively
in about 5 to 10 minutes. This initial screening without
blood testing could lead to the quick initiation of treat-
ment without the added cost or inconvenience of labora-
tory testing. This would also minimize any potential loss
to follow-up due to the extra step in testing.
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